vs
Side-by-side financial comparison of AVAX ONE TECHNOLOGY LTD. (AVX) and RELMADA THERAPEUTICS, INC. (RLMD). Click either name above to swap in a different company.
RELMADA THERAPEUTICS, INC. is the larger business by last-quarter revenue ($1.3M vs $1.0M, roughly 1.2× AVAX ONE TECHNOLOGY LTD.).
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing novel therapies for central nervous system disorders. Its lead product candidate targets treatment-resistant depression, with ongoing clinical trials to address unmet medical needs in its primary markets of North America and Europe.
AVX vs RLMD — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2023
| Metric | | |
|---|---|---|
| Revenue | $1.0M | $1.3M |
| Net Profit | $-16.6M | — |
| Gross Margin | — | — |
| Operating Margin | -1522.1% | -2130.6% |
| Net Margin | -1633.6% | — |
| Revenue YoY | — | 13.0% |
| Net Profit YoY | -480.2% | — |
| EPS (diluted) | $32.17 | $-0.84 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.0M | — | ||
| Q3 25 | $525.9K | — | ||
| Q2 25 | $452.0K | — | ||
| Q1 25 | $344.4K | — | ||
| Q3 24 | $0 | — | ||
| Q2 24 | $41.3K | — | ||
| Q4 23 | — | $1.3M | ||
| Q3 23 | — | $1.3M |
| Q4 25 | $-16.6M | — | ||
| Q3 25 | $-8.4M | — | ||
| Q2 25 | $-8.1M | — | ||
| Q1 25 | $-145.5K | — | ||
| Q3 24 | $-5.8M | — | ||
| Q2 24 | $-4.2M | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | $-22.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 22.9% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 18.4% | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — |
| Q4 25 | -1522.1% | — | ||
| Q3 25 | -496.6% | — | ||
| Q2 25 | -328.4% | — | ||
| Q1 25 | -600.0% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -2827.7% | — | ||
| Q4 23 | — | -2130.6% | ||
| Q3 23 | — | -1717.3% |
| Q4 25 | -1633.6% | — | ||
| Q3 25 | -1588.0% | — | ||
| Q2 25 | -1783.4% | — | ||
| Q1 25 | -42.2% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -10243.5% | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | -1665.0% |
| Q4 25 | $32.17 | — | ||
| Q3 25 | $-5.55 | — | ||
| Q2 25 | $-27.60 | — | ||
| Q1 25 | $-1.17 | — | ||
| Q3 24 | $-57.19 | — | ||
| Q2 24 | $-83.03 | — | ||
| Q4 23 | — | $-0.84 | ||
| Q3 23 | — | $-0.73 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $22.1M | $96.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $187.0M | $85.4M |
| Total Assets | $195.0M | $97.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $22.1M | — | ||
| Q3 25 | $894.7K | — | ||
| Q2 25 | $185.3K | — | ||
| Q1 25 | $1.4M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q4 23 | — | $96.3M | ||
| Q3 23 | — | $106.3M |
| Q4 25 | — | — | ||
| Q3 25 | $1.8M | — | ||
| Q2 25 | $8.6M | — | ||
| Q1 25 | $10.2M | — | ||
| Q3 24 | $2.2M | — | ||
| Q2 24 | $3.1M | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — |
| Q4 25 | $187.0M | — | ||
| Q3 25 | $12.2M | — | ||
| Q2 25 | $4.1M | — | ||
| Q1 25 | $6.4M | — | ||
| Q3 24 | $6.7M | — | ||
| Q2 24 | $11.3M | — | ||
| Q4 23 | — | $85.4M | ||
| Q3 23 | — | $100.7M |
| Q4 25 | $195.0M | — | ||
| Q3 25 | $16.5M | — | ||
| Q2 25 | $15.2M | — | ||
| Q1 25 | $16.8M | — | ||
| Q3 24 | $10.8M | — | ||
| Q2 24 | $15.7M | — | ||
| Q4 23 | — | $97.6M | ||
| Q3 23 | — | $109.1M |
| Q4 25 | — | — | ||
| Q3 25 | 0.15× | — | ||
| Q2 25 | 2.11× | — | ||
| Q1 25 | 1.59× | — | ||
| Q3 24 | 0.33× | — | ||
| Q2 24 | 0.28× | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-14.4M | $-10.2M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-14.4M | — | ||
| Q3 25 | $-2.4M | — | ||
| Q2 25 | $-884.1K | — | ||
| Q1 25 | $-2.2M | — | ||
| Q3 24 | $-1.2M | — | ||
| Q2 24 | $-919.2K | — | ||
| Q4 23 | — | $-10.2M | ||
| Q3 23 | — | $-11.6M |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
